30.05
-0.65(-2.12%)
Currency In USD
| Previous Close | 30.7 |
| Open | 30.53 |
| Day High | 30.83 |
| Day Low | 29.56 |
| 52-Week High | 45.85 |
| 52-Week Low | 9.43 |
| Volume | 439,571 |
| Average Volume | 570,601 |
| Market Cap | 1.01B |
| PE | -13.85 |
| EPS | -2.17 |
| Moving Average 50 Days | 31.92 |
| Moving Average 200 Days | 27.35 |
| Change | -0.65 |
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
GlobeNewswire Inc.
Mar 10, 2026 12:00 PM GMT
CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of e
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
GlobeNewswire Inc.
Mar 09, 2026 2:21 PM GMT
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows. CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Bio
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, developm